Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: A prospective and descriptive study of 19 patients

被引:17
作者
Boucas Vasconcelos De Noronha E Meneze, Nuno Miguel
Lima, Ricardo
Moreira, Ana
Varela, Paulo
Barroso, Ana
Baptista, Armando
Parente, Barbara
机构
[1] Serviço de Dermatologia e Venereologia, Centro Hospitalar de V. N. de Gaia, Espinho
[2] Unidade de Pneumologia Oncológica, Serviço de Pneumologia, Centro Hospitalar de V. N. de Gaia, Espinho
关键词
cetuximab; cutaneous side-effects; erlotinib and papulopustular eruption; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; SOLID TUMORS; PHASE-I; ZD1839; TRIAL; GEFITINIB;
D O I
10.1684/ejd.2009.0650
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Erlotinib and cetuximab are human epidermal growth factor receptor inhibitors (EGFRI) that are approved in monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Papulopustular eruptions are the most frequent adverse effect, their occurrence being associated with increased survival in some studies. We describe 19 patients who presented with a rash located mainly to the face and trunk, without presence of comedones, shortly after initiation of EGFRI therapy. We present our algorithm to manage these patients and their respective responses. We also report other therapeutic options and cutaneous alterations that may be seen.
引用
收藏
页码:248 / 251
页数:4
相关论文
共 19 条
[1]   Dermatologic side effects associated with the epidermal growth factor receptor inhibitors [J].
Agero, Anna Liza C. ;
Dusza, Stephen W. ;
Benvenuto-Andrade, Cristiane ;
Busam, Klaus J. ;
Myskowski, Patricia ;
Halpern, Allan C. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :657-670
[2]  
[Anonymous], 2003, P AM SOC CLIN ONCOL
[3]   Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 [J].
Busam, KJ ;
Capodieci, P ;
Motzer, R ;
Kiehn, T ;
Phelan, D ;
Halpern, AC .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (06) :1169-1176
[4]   Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor [J].
Fernandez-Galar, M ;
España, A ;
López-Picazo, JM .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2004, 29 (02) :138-140
[5]  
Herbst Roy S, 2003, Clin Lung Cancer, V4, P366, DOI 10.3816/CLC.2003.n.016
[6]   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].
Herbst, RS ;
Giaccone, G ;
Schiller, JH ;
Natale, RB ;
Miller, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794
[7]   Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial [J].
Herbst, RS ;
Maddox, AM ;
Small, EJ ;
Rothenberg, L ;
Small, EL ;
Rubin, EH ;
Baselga, J ;
Rojo, F ;
Hong, WK ;
Swaisland, H ;
Averbuch, SD ;
Ochs, J ;
LoRusso, PM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3815-3825
[8]   Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].
Hidalgo, M ;
Siu, LL ;
Nemunaitis, J ;
Rizzo, J ;
Hammond, LA ;
Takimoto, C ;
Eckhardt, SG ;
Tolcher, A ;
Britten, CD ;
Denis, L ;
Ferrante, K ;
Von Hoff, DD ;
Silberman, S ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279
[9]   Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors [J].
Kimyai-Asadi, A ;
Jih, MH .
ARCHIVES OF DERMATOLOGY, 2002, 138 (01) :129-131
[10]   COMPARISON OF EPIDERMAL GROWTH-FACTOR BINDING AND RECEPTOR DISTRIBUTION IN NORMAL HUMAN-EPIDERMIS AND EPIDERMAL APPENDAGES [J].
NANNEY, LB ;
MAGID, M ;
STOSCHECK, CM ;
KING, LE .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1984, 83 (05) :385-393